Bulbospinal Muscular Atrophy (Spinal and Bulbar Muscular Atrophy/Kennedy Disease): Research Report

Scope and evidence date. “Bulbospinal muscular atrophy” here denotes spinal and bulbar muscular atrophy (SBMA), or Kennedy disease, not SMN1-associated 5q spinal muscular atrophy. Evidence below is disease-level aggregate literature, population genomics, clinical-trial registries, and experimental models—not individual-patient EHR data. Sources were reviewed through the retrieved 2024 literature; trial-registry records may contain later status updates. PMID was not exposed in the retrieved records, so DOI and ClinicalTrials.gov identifiers are supplied rather than guessing PMIDs.

The following table provides a compact curation layer; the narrative then addresses all requested domains.

Table: This table condenses the key disease-knowledge-base fields for spinal and bulbar muscular atrophy/Kennedy disease, including identifiers, genetics, phenotypes, mechanism, epidemiology, diagnostics, management, and recent trials. It is designed for rapid curation while keeping claims conservative and tied to cited conversation evidence.

1. Disease information

SBMA is a rare, chronic, adult-onset, X-linked neuromuscular disease caused by an expanded CAG repeat in exon 1 of AR, encoding an abnormally long polyglutamine tract in the androgen receptor. It combines slowly progressive lower-motor-neuron and primary skeletal-muscle disease with partial androgen insensitivity and metabolic manifestations. Bulbar dysfunction usually appears later than limb weakness. It is distinct from childhood 5q-SMA and typically progresses much more slowly than amyotrophic lateral sclerosis (ALS). (pradat2020thefrenchnational pages 1-2, zanovello2023unexpectedfrequencyof pages 1-2)

Identifiers and synonyms

• Preferred names: spinal and bulbar muscular atrophy; SBMA; Kennedy disease.
• Alternatives: bulbospinal muscular atrophy; X-linked bulbospinal neuronopathy; X-linked spinal and bulbar muscular atrophy; Kennedy syndrome.
• MONDO: MONDO:0016113.
• OMIM: 313200.
• Orphanet: ORPHA:481.
• MeSH: D055534, Bulbo-Spinal Atrophy, X-Linked; the trial-registry hierarchy also places it under motor-neuron, neuromuscular, hereditary neurodegenerative, and X-linked genetic diseases. (NCT06169046 chunk 1)
• ICD: SBMA lacks a consistently disease-specific ICD-10-CM code and is generally represented under broader spinal muscular atrophy/motor-neuron disease categories; coding should be jurisdiction-specific. ICD-11 likewise should be verified against the deployment used by the knowledge base rather than inferred from an older ICD-10 mapping.

The French national protocol describes it as “a rare, adult-onset, X-linked recessive neuromuscular disease caused by CAG expansions in exon 1 of the androgen receptor gene.” [Published April 2020; DOI URL: https://doi.org/10.1186/s13023-020-01366-z.] (pradat2020thefrenchnational pages 1-2)

2. Etiology, risk, protection, and gene–environment interaction

Causal factor

The necessary inherited lesion is a germline CAG-repeat expansion in AR at Xq12. Most current clinical and population-genomic sources define a pathogenic allele as ≥38 CAG repeats, although conventional reviews often describe unaffected and disease ranges as approximately 9/11–36 and 39–72, respectively. Borderline alleles require careful laboratory interpretation and phenotype correlation. (hashizume2020diseasemechanismbiomarker pages 8-12, cantara2024antisenseoligonucleotides(asos) pages 14-16, zanovello2023unexpectedfrequencyof pages 1-2)

The expansion produces two linked effects: partial impairment of normal AR activity, explaining androgen-insensitivity features, and a dominant toxic gain of function of ligand-bound polyglutamine-expanded AR in vulnerable tissues. Longer repeats correlate strongly with earlier onset and often greater severity, but explain only part of phenotypic variability and do not reliably determine an individual progression rate. (hashizume2020diseasemechanismbiomarker pages 8-12, querin2017kennedydisease(xlinked pages 1-5, badders2018selectivemodulationof pages 1-3)

Risk factors

• Genetic: a pathogenic AR expansion; longer repeat length; an affected maternal lineage; and population founder effects reported in Finnish, Japanese, and Italian groups. No second locus has reached the status of a routinely actionable clinical modifier. (hashizume2020diseasemechanismbiomarker pages 8-12)
• Sex and hormones: high post-pubertal androgen exposure is the major biological context determining penetrance. Full disease is overwhelmingly male; heterozygous females are usually asymptomatic or mildly affected because of lower androgen exposure and X-inactivation mosaicism. (pradat2020thefrenchnational pages 1-2, badders2018selectivemodulationof pages 1-3)
• Age: penetrance is age-dependent; onset is commonly in the fourth or fifth decade, although reported ranges extend from about 18 to 64 years. (querin2017kennedydisease(xlinked pages 1-5, cantara2024antisenseoligonucleotides(asos) pages 14-16)
• Environmental/lifestyle: no toxin, infection, smoking exposure, occupation, diet, or alcohol exposure has been established as a cause. Reduced activity, obesity, dyslipidemia, and insulin resistance can aggravate disability or cardiometabolic burden but are not proven initiators.

Protective factors and gene–environment interaction

No validated naturally protective human AR allele or environmental exposure prevents SBMA. Lower androgen signaling is protective in female carriers and in castrated or hormonally manipulated animal models, but pharmacological androgen deprivation has anabolic, sexual, skeletal, and metabolic costs and is not established preventive therapy. The clearest gene–environment-like interaction is therefore expanded AR × androgen ligand: testosterone or dihydrotestosterone binding promotes AR activation, nuclear entry, altered co-regulator engagement, and toxicity. (hashizume2020diseasemechanismbiomarker pages 8-12, iida2019srcinhibitionattenuates pages 1-2, badders2018selectivemodulationof pages 1-3)

3. Phenotypes

Quality of life. Progressive weakness, fatigue, falls, loss of ambulation, speech/swallowing limitations, fertility concerns, and dependence in eating and other activities substantially reduce quality of life. Some patients ultimately require wheelchairs and assistance with daily tasks. Clinical studies use SF-36, ALSAQ-40, INQoL, SBMAFRS, AMAT, 2MWT, and 6MWT; however, robust phenotype-specific utility weights such as EQ-5D norms remain sparse. (querin2017kennedydisease(xlinked pages 15-19, NCT00303446 chunk 1, NCT06169046 chunk 1, badders2018selectivemodulationof pages 1-3)

4. Genetic and molecular information

• Causal gene: AR, androgen receptor; HGNC:644; NCBI Gene:367; OMIM gene 313700. The pathogenic repeat lies in exon 1 and expands the N-terminal polyglutamine tract.
• Variant class: germline, X-linked short tandem repeat expansion; HGVS representations should state the assay-derived repeat number rather than treating the disorder as a conventional SNV. It is a toxic gain-of-function allele with partial AR loss of normal function.
• Classification: expansions in the established disease range are pathogenic; borderline 36–38-repeat calls show laboratory and literature variability and require expert interpretation. Ordinary WES may not size the expansion reliably.
• Population frequency: a 2023 WGS study of 74,277 unrelated individuals found an expansion frequency of 1:3,182 X chromosomes (95% CI 1:2,309–1:4,386; denominator 117,734 X chromosomes). Its WGS pipeline showed 100% sensitivity, 99% specificity, and 97.4% positive predictive value against fragment-PCR sizing. [Received July 28, 2022; published online February 17, 2023; https://doi.org/10.1093/brain/awad050.] (zanovello2023unexpectedfrequencyof pages 1-2)
• Modifier genes: putative modifiers include proteostasis/chaperone, co-regulator, transcriptional, and metabolic pathways, but no modifier is recommended for routine predictive testing.
• Epigenetics: altered chromatin/co-regulator engagement and transcription are integral downstream effects of mutant AR, but no validated diagnostic DNA-methylation signature or epigenetic therapy exists.
• Chromosomal abnormalities: no recurrent deletion, translocation, inversion, aneuploidy, or copy-number alteration defines classic SBMA; CMA, karyotyping, and FISH are therefore not first-line tests.
• Somatic instability/mosaicism: repeat sizing can vary modestly by tissue and assay, but classic disease is inherited through a germline X-chromosomal expansion; somatic cancer-style testing is not relevant.

5. Environmental information

No infectious agent, toxin, radiation exposure, pollution, or occupational exposure is established as causal or triggering. SBMA is not communicable. Lifestyle factors principally modify complications: appropriate activity may preserve conditioning, whereas inactivity, obesity, poor nutrition, and cardiometabolic disease can worsen function. Excessively fatiguing exercise should be avoided and programs individualized. Alcohol, smoking, and specific diets have no proven disease-modifying effect. The biologically decisive non-genetic exposure is endogenous androgen after puberty. (querin2017kennedydisease(xlinked pages 12-15, badders2018selectivemodulationof pages 1-3)

6. Mechanism and pathophysiology

Causal chain

1. Upstream genetic trigger: expanded AR CAG repeat → elongated AR polyglutamine tract.
2. Ligand activation: testosterone/DHT binding causes conformational activation and nuclear translocation.
3. Protein toxicity: mutant AR misfolding, soluble oligomers/inclusions, abnormal AF-2 co-regulator binding, and impaired proteostasis alter transcription, trafficking, ubiquitin–proteasome and autophagy functions.
4. Cellular stress: mitochondrial dysfunction, oxidative stress, disturbed creatine handling, and aberrant Src–p130Cas/STAT3 signaling develop.
5. Tissue pathology: both lower motor neurons and skeletal myofibers are primary targets; denervation and cell-autonomous myofiber toxicity reinforce one another at the motor unit.
6. Clinical output: progressive weakness/atrophy, fasciculations, bulbar dysfunction, impaired cough, sensory abnormalities, and systemic androgen/metabolic manifestations. (hashizume2020diseasemechanismbiomarker pages 1-5, hashizume2020diseasemechanismbiomarker pages 8-12, cortes2014motorneurondegeneration pages 1-2, iida2019srcinhibitionattenuates pages 1-2)

Human and model evidence

Human pathology and imaging show lower-motor-neuron loss plus mixed neurogenic and myopathic muscle changes. Skeletal muscle loses fast type-II fibers, relatively increases type-I fibers, and shifts from glycolytic toward oxidative metabolism. Serum creatinine begins declining before clinically evident weakness, supporting a preclinical muscle phase. (hashizume2020diseasemechanismbiomarker pages 1-5, hashizume2020diseasemechanismbiomarker pages 8-12)

The strongest experimental evidence that muscle is causal comes from BAC fxAR121 mice: muscle-specific excision of mutant AR completely rescued neuromuscular phenotypes despite persistent CNS expression, while peripheral AR-targeting ASO rescued weakness and premature death. This establishes skeletal muscle as a therapeutic target but does not prove that neuronal targeting is unnecessary in humans. (cortes2014motorneurondegeneration pages 1-2)

A phosphoprotein screen in AR-97Q mice found phosphorylated Src increased in spinal cord and muscle before symptoms; p130Cas was identified downstream, and Src inhibition improved behavioral and histopathological phenotypes. Increased p-Src was also observed in human autopsy spinal cord and muscle, providing cross-species support, although therapeutic efficacy remains preclinical. [Published September 2019; https://doi.org/10.1038/s41467-019-12282-7.] (iida2019srcinhibitionattenuates pages 1-2)

AF-2-domain screening in Drosophila identified tolfenamic acid and MEPB; MEPB then dose-dependently improved body weight, rotarod performance, grip strength, neuronal loss, neurogenic atrophy, and testicular atrophy in a mouse model. This validates selective AR co-regulator modulation as an androgen-sparing strategy, not as an approved treatment. [Published May 2018; https://doi.org/10.1038/nm.4500.] (badders2018selectivemodulationof pages 1-3)

Molecular profiling and ontology suggestions

• Transcriptomics: transcriptional dysregulation is established, including impaired muscular creatine-transporter SLC6A8 expression, but no transcriptomic panel is clinically validated. (iida2019srcinhibitionattenuates pages 1-2)
• Proteomics/phosphoproteomics: pre-onset Src/STAT3-pathway activation in mouse spinal cord and muscle; human tissue validation for p-Src. (iida2019srcinhibitionattenuates pages 1-2)
• Metabolomics/lipidomics: glycolytic-to-oxidative switching, insulin resistance, dyslipidemia, fatty liver, and mitochondrial deficits are reported; no diagnostic metabolomic signature exists. (hashizume2020diseasemechanismbiomarker pages 1-5, zanovello2023unexpectedfrequencyof pages 1-2)
• Single-cell/spatial/multi-omics: no mature, replicated human single-cell or spatial atlas is ready for diagnostic implementation. These are important evidence gaps.
• Functional screens: Drosophila compound screens, conditional mouse genetics, ASO experiments, and phosphoprotein assays have nominated AF-2, AR RNA, muscle AR, and Src as targets. (cortes2014motorneurondegeneration pages 1-2, iida2019srcinhibitionattenuates pages 1-2, badders2018selectivemodulationof pages 1-3)

Suggested terms: GO:0005634 nucleus; GO:0005739 mitochondrion; GO:0005776 autophagosome; GO terms for androgen-receptor signaling, protein folding, macroautophagy, mitochondrial organization, oxidative stress response, skeletal-muscle atrophy, and motor-neuron apoptotic process. Cell terms include CL:0000100 motor neuron, CL:0000187 muscle cell/myocyte, skeletal myofiber, and dorsal-root-ganglion sensory neuron.

7. Anatomical structures affected

• Primary nervous structures: spinal-cord anterior horn and brainstem motor nuclei; motor axons and motor units. Suggested anatomy: UBERON spinal cord, ventral horn, brainstem, peripheral nerve, neuromuscular junction.
• Primary muscular structures: proximal lower-limb muscle early, followed by upper limbs, facial, masticatory, tongue, pharyngeal, laryngeal, and respiratory muscles. UBERON:0001134 skeletal muscle tissue.
• Sensory system: dorsal-root ganglia and sensory axons explain reduced sensory action potentials and sensory symptoms. (querin2017kennedydisease(xlinked pages 5-9)
• Secondary/systemic sites: testes, breast tissue, liver, adipose tissue, pancreas/metabolic system, and possibly cardiac conduction tissue.
• Subcellular: nucleus and cytoplasm for mutant AR; mitochondria, proteasome/autophagy–lysosome machinery, and sarcomeric/myofiber compartments.
• Laterality: generally bilateral and relatively symmetric, although functional asymmetry can occur; focal unilateral disease is atypical.

8. Temporal development

SBMA is chronic and insidious. Tremor, cramps, CK elevation, or declining creatinine can precede weakness by years; hand tremor may precede weakness by more than a decade. Typical weakness onset is 30–50 years, with a mean of approximately 43 years in the 2023 genomic-study background. Lower-limb weakness usually precedes upper-limb and bulbar impairment. (hashizume2020diseasemechanismbiomarker pages 1-5, querin2017kennedydisease(xlinked pages 1-5, zanovello2023unexpectedfrequencyof pages 1-2)

Progression is lifelong and approximately linear only at a cohort level; a 2024 ASO review cites about 2% annual muscle-strength decline. Individual trajectories vary. One review reported mean life expectancy of 71.3 years and mean disease duration of 27.3 years, but these older cohort estimates should not be interpreted as universal survival predictions. There is no relapsing-remitting course or spontaneous remission. (querin2017kennedydisease(xlinked pages 1-5, cantara2024antisenseoligonucleotides(asos) pages 14-16)

Clinically useful stages are: prodromal biochemical/tremor phase; early ambulatory limb weakness; intermediate multisystem and bulbar involvement; advanced loss of ambulation with aspiration/cough risk. Early molecular intervention is theoretically preferable before irreversible motor-unit loss, but no validated human treatment window has been defined.

9. Inheritance and population epidemiology

SBMA is X-linked. A heterozygous mother has a 50% probability of transmitting the expanded allele in each pregnancy; sons inheriting it are at high age-dependent risk of disease, while daughters become carriers and usually have no or minor neuromuscular manifestations. An affected male transmits the expansion to all daughters and no sons. Penetrance in expansion-positive males is substantial but appears age- and repeat-dependent rather than absolutely complete, especially near the threshold. Expressivity is variable. Anticipation may occur through intergenerational repeat change, but it is less predictable than in some repeat disorders; counseling should not promise a specific onset from repeat length. Consanguinity is not relevant to X-linked transmission, and germline mosaicism is not a major recognized mechanism.

Classical prevalence estimates are 1–2 per 100,000 or about 1:30,000 males; older incidence estimates include approximately 1:400,000/year. Geographic clusters include Finland’s Vasa region, where 13 cases among 85,000 males yielded 1:6,538, historically attributed to a founder effect. (hashizume2020diseasemechanismbiomarker pages 1-5, querin2017kennedydisease(xlinked pages 1-5, zanovello2023unexpectedfrequencyof pages 1-2)

The pivotal 2023 WGS analysis found pathogenic expansions roughly tenfold more frequently than classical diagnosed prevalence and modeled male disease prevalence at 1:6,887, more than fourfold above the commonly reported estimate. The authors explicitly concluded that the discrepancy may reflect “underdiagnosis…reduced penetrance, and/or pleomorphic clinical manifestations.” This is a modeled prevalence—not a population-screened clinical case count. (zanovello2023unexpectedfrequencyof pages 1-2)

Men comprise nearly all fully affected patients; female carriers can have cramps, tremor, or mild weakness. Founder effects and diagnostic access produce geographic variation. A current carrier frequency cannot be reduced to one global figure beyond the 2023 estimate of approximately 1:3,182 X chromosomes in the aggregated genomic cohorts.

10. Diagnostics

Recommended pathway

1. Suspect SBMA in an adult man with slowly progressive lower-motor-neuron weakness, often lower-limb predominant, plus tremor/cramps, bulbar dysfunction, gynecomastia, infertility, sensory abnormalities, high CK, or a compatible maternal family history.
2. Perform neurologic, bulbar, respiratory, endocrine/metabolic, reproductive, and cardiac assessment.
3. Confirm with targeted AR CAG-repeat sizing, generally fragment-length PCR with an expansion-appropriate validated assay.
4. Use EMG/NCS, CK, creatinine, liver enzymes, glucose/HbA1c, lipid profile, ECG, pulmonary function, and swallow assessment to characterize burden and exclude mimics. The French consensus recommends initial evaluation in a specialist motor-neuron/neuromuscular center. (pradat2020thefrenchnational pages 1-2)

Tests and biomarkers

• EMG: diffuse chronic denervation/reinnervation; fasciculations may occur. Sensory NCS can show reduced SNAPs despite modest symptoms. (pradat2020thefrenchnational pages 1-2, querin2017kennedydisease(xlinked pages 5-9)
• Blood: elevated CK and transaminases of muscle origin; falling creatinine correlates with muscle loss and may precede weakness. Glucose, lipids, and liver indices identify systemic disease. (hashizume2020diseasemechanismbiomarker pages 1-5)
• Functional: SBMAFRS, AMAT, quantitative muscle testing, grip strength, timed up-and-go, 2MWT/6MWT, tongue pressure, FVC and peak expiratory flow.
• Imaging: muscle MRI, fat fraction/infiltration, and lean muscle volume are promising progression and pharmacodynamic biomarkers; they are not diagnostic substitutes for genetic testing. (hashizume2020diseasemechanismbiomarker pages 1-5, NCT06411912 chunk 1)
• Swallowing: clinical examination and instrumental videofluoroscopic or endoscopic assessment when choking, weight loss, or recurrent infection occurs.
• Biopsy: usually unnecessary after molecular confirmation; if performed, muscle can show mixed neurogenic group atrophy and myopathic changes. Nerve or spinal-cord biopsy has no clinical role.

Genetic modalities

Targeted repeat-expansion testing is first line. WGS can detect the expansion using validated repeat callers plus orthogonal confirmation—the 2023 ExpansionHunter pipeline performed well—but routine short-read WES, ordinary multigene panels without repeat analysis, CMA, karyotyping, FISH, and mitochondrial-DNA testing can miss or do not address the causal lesion. RNA-seq, proteomics, metabolomics, epigenomics, and liquid biopsy remain research tools. (zanovello2023unexpectedfrequencyof pages 1-2)

Differential diagnosis and screening

Key mimics are ALS, progressive muscular atrophy, other non-5q hereditary motor neuropathies/SMA, limb-girdle muscular dystrophy, inflammatory myopathy, inclusion-body myositis, myotonic dystrophy, Pompe disease, and Charcot–Marie–Tooth disease. Sensory abnormalities, endocrine signs, very slow progression, maternal X-linked history, and AR testing favor SBMA over ALS. (querin2017kennedydisease(xlinked pages 5-9)

Population or newborn screening is not standard because SBMA is adult-onset, rare, and lacks an approved presymptomatic disease-modifying therapy. Cascade testing of at-risk adult relatives is appropriate after genetic counseling. Prenatal and preimplantation genetic testing are technically possible once the familial expansion is documented.

11. Outcome and prognosis

SBMA usually progresses more slowly and has longer survival than ALS. There are no broadly validated 5- or 10-year survival tables. Older aggregate data reported mean life expectancy around 71.3 years and mean duration 27.3 years, but ascertainment, geography, repeat size, and supportive care limit generalizability. (querin2017kennedydisease(xlinked pages 1-5)

Major morbidity includes falls, fractures, loss of ambulation, fatigue, chronic pain/cramps, communication and swallowing disability, malnutrition, aspiration, sexual/reproductive dysfunction, diabetes/dyslipidemia/fatty liver, and caregiver dependence. Respiratory infectious disease accounts for more than half of deaths in one review, with aspiration pneumonia a prominent mechanism; invasive ventilatory failure is comparatively uncommon. (hashizume2020diseasemechanismbiomarker pages 1-5, querin2017kennedydisease(xlinked pages 12-15)

Earlier onset is associated with longer CAG length. Functional baseline, bulbar involvement, mobility, cough/swallow safety, body composition, and cardiometabolic disease are clinically meaningful prognostic features. Creatinine, muscle MRI fat fraction/volume, 6MWT, and SBMAFRS are promising longitudinal markers, but none independently predicts an individual outcome with sufficient accuracy for deterministic counseling. (hashizume2020diseasemechanismbiomarker pages 1-5, querin2017kennedydisease(xlinked pages 15-19)

12. Treatment and current applications

Current real-world standard

There is no approved, proven disease-modifying treatment. Multidisciplinary supportive care is standard: individualized physiotherapy and moderate exercise; occupational therapy, mobility aids, fall prevention and orthoses; speech/communication therapy; swallow and dietetic assessment; texture modification and gastrostomy when necessary; cough augmentation, breath stacking, secretion clearance, vaccination, and prompt treatment of respiratory infection; pain/cramp treatment; and management of diabetes, dyslipidemia, fatty liver, erectile dysfunction, and fertility concerns. Non-invasive ventilation is needed less often than in ALS but should be used when physiologically indicated. Testosterone replacement is not supported and may theoretically worsen ligand-dependent toxicity. (pradat2020thefrenchnational pages 1-2)

Suggested NCIT intervention concepts include physical therapy, occupational therapy, speech therapy, nutritional support, gastrostomy, noninvasive ventilation, cough-assist therapy, genetic counseling, and supportive care. Drug concepts should be annotated as investigational unless approved for another indication.

Historical pharmacological programs

• Leuprorelin/GnRH agonism: reduced mutant AR accumulation and showed possible swallowing signals in small studies, but efficacy was insufficient to establish routine therapy and anti-androgen adverse effects include sexual dysfunction and loss of anabolic muscle support. (hashizume2020diseasemechanismbiomarker pages 1-5, iida2019srcinhibitionattenuates pages 1-2)
• Dutasteride: NIH phase 2, randomized quadruple-masked trial, actual n=57, 0.5 mg/day for 24 months; primary endpoint was quantitative muscle-strength change with functional, SF-36, neurophysiological, hormone, and CK outcomes. It did not establish an effective standard treatment. ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT00303446. (NCT00303446 chunk 1)
• BVS857, an IGF-1 mimetic: completed phase 2, n=37, assessing safety and MRI thigh-muscle volume; immunogenicity and limited preliminary efficacy prevented clinical adoption. ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT02024932. (NCT02024932 chunk 1)
• Clenbuterol: a small earlier cohort suggested motor improvement but CK elevation and cardiovascular concerns remained; it is not standard care. (querin2017kennedydisease(xlinked pages 12-15)

Recent development pipeline

• AJ201/JM17: completed phase 1/2a randomized study (2023–April 2024), n=25, 600 mg/day for 12 weeks. It evaluated safety, PK, and change in mutant AR protein in skeletal-muscle biopsies; no efficacy conclusion should be drawn from a registry record without peer-reviewed results. https://clinicaltrials.gov/study/NCT05517603. (NCT05517603 chunk 1)
• NIDO-361, PIONEER KD: phase 2 randomized placebo-controlled study begun March 2024, actual n=54, oral 100 mg then 200 mg daily for 12 months. Primary measures include thigh/whole-body lean-muscle volume and safety; secondary measures include m-SBMAFRS, walking, actigraphy, and grip. The registry later lists completion, but peer-reviewed clinical efficacy was not present in the retrieved 2023–2024 evidence. https://clinicaltrials.gov/study/NCT06411912. (NCT06411912 chunk 1)
• BetaSBMA clenbuterol: phase 2, estimated n=90, 0.04 mg/day for 48 weeks; primary endpoint 6MWT, with SBMAFRS, AMAT, FVC, creatinine, ALSAQ-40, and INQoL. https://clinicaltrials.gov/study/NCT06169046. (NCT06169046 chunk 1)
• Mexiletine Med-SBMA: phase 2/3 study initiated in 2025, estimated n=68, 300 mg/day for 12 weeks; measures ALSFRS-R/SBMAFRS, strength, tongue pressure, walking, FVC and PEF. It excludes Brugada-pattern ECG and significant conduction disease. https://clinicaltrials.gov/study/NCT06862596. This is a post-2024 registry development, included for current context. (NCT06862596 chunk 1)

Advanced therapeutics

AR-lowering ASOs and siRNAs improve disease in mice, including near-complete AR-protein reduction and phenotypic rescue; key translational problems are safe chronic suppression, preserving normal AR function, and delivery to both muscle and CNS. A 2024 review states that ASOs can “decrease levels of toxic proteins” and identifies SBMA as an active target, but no SBMA ASO is approved. [April 2024; https://doi.org/10.3390/ijms25094809.] (cantara2024antisenseoligonucleotides(asos) pages 14-16)

Gene replacement is inappropriate for a toxic gain-of-function allele; editing or allele-selective silencing is conceptually attractive but preclinical. Stem-cell therapy, immunotherapy, and surgery do not address the causal disease. There is no validated SBMA pharmacogenomic dosing guideline or combination algorithm.

13. Prevention

Primary lifestyle prevention is not possible because the initiating lesion is inherited. Prevention is therefore reproductive and complication-oriented:

• Primary/genetic: pedigree assessment, genetic counseling, informed carrier/cascade testing, and discussion of preimplantation or prenatal testing. Testing minors for an adult-onset condition without childhood intervention generally requires careful ethical justification.
• Secondary: recognize tremor, cramps, high CK, gynecomastia, sensory NCS abnormalities, or family history early; confirm molecularly and establish baseline swallow, respiratory, cardiac, metabolic, and functional assessments.
• Tertiary: fall prevention, tailored exercise, healthy weight and metabolic control, aspiration precautions, cough augmentation, nutrition support, respiratory-infection vaccination according to national schedules, and prompt treatment of pneumonia. Vaccines prevent infections, not SBMA itself. (pradat2020thefrenchnational pages 1-2, querin2017kennedydisease(xlinked pages 12-15)

No prophylactic anti-androgen, ASO, vitamin, diet, or supplement has established benefit in asymptomatic carriers.

14. Other species and natural disease

AR orthologs are highly conserved across mammals and are present in mouse (Mus musculus, NCBI Taxon 10090), rat (Rattus norvegicus, 10116), dog (Canis lupus familiaris, 9615), zebrafish (Danio rerio, 7955), fruit fly (Drosophila melanogaster, 7227; nuclear-receptor modeling rather than a direct human-equivalent AR physiology), and nematodes. No well-established naturally occurring companion-animal or wildlife disease caused by the homologous pathogenic polyglutamine expansion was identified in the retrieved evidence. Thus, veterinary breed/VBO associations and natural cross-species prevalence are not established.

There is no infectious transmission, zoonotic potential, or cross-species contagion. Comparative value comes from conserved steroid-receptor activation, proteostasis, transcription, and muscle–motor-neuron interactions rather than natural disease.

15. Model organisms and experimental systems

• Transgenic and knock-in mice: AR-97Q and other expanded-AR lines reproduce androgen-dependent weakness, atrophy, motor-neuron and muscle pathology, nuclear AR accumulation, endocrine abnormalities, and shortened survival. They enabled Src-inhibitor, hormonal, chaperone, IGF-1, and ASO studies. BAC fxAR121 conditional mice demonstrated muscle-driven disease. Limitations include very long repeats, supraphysiologic expression, rapid course, strain/sex effects, and incomplete replication of decades-long human disease. (cortes2014motorneurondegeneration pages 1-2, iida2019srcinhibitionattenuates pages 1-2)
• Drosophila: expanded human AR causes androgen-dependent lethality, locomotor and neuromuscular-junction defects; its speed and genetic tractability enabled AF-2 compound screening. Limitations are divergent endocrine physiology and simplified neuromuscular anatomy. (badders2018selectivemodulationof pages 1-3)
• Cellular systems: transfected neuronal and muscle lines, primary myotubes, and patient-derived cells support studies of AR localization, aggregation, transcription, autophagy, mitochondria, Src/p130Cas, and oligonucleotide knockdown. They lack intact motor-unit and endocrine physiology.
• Patient iPSC-derived motor neurons/myocytes and co-cultures: promising for isogenic CRISPR controls and human-specific drug screening, but maturation, aging, and systemic androgen exposure remain limitations.
• Organoids/spatial systems: not yet validated as standard SBMA models.

Model resources should be sought in MGI, IMSR/MMRRC, FlyBase, Cellosaurus, GEO/SRA, and relevant patient-biobank repositories. The most informative translational strategy is triangulation across muscle, motor-neuron, and whole-animal systems rather than reliance on a single model.

Expert synthesis and evidence gaps

The contemporary view is that SBMA is not simply a motor-neuron disease: it is an androgen-dependent, multisystem polyglutamine disorder in which skeletal muscle is an initiating and therapeutically important compartment. This view is supported by human mixed neurogenic/myopathic pathology, preclinical muscle-specific rescue, and muscle-focused biomarkers and trials. (hashizume2020diseasemechanismbiomarker pages 1-5, cortes2014motorneurondegeneration pages 1-2)

The most consequential recent epidemiologic development is the 2023 observation that pathogenic AR expansions may be much more common than diagnosed SBMA. It argues for greater diagnostic vigilance in adult men labeled with ALS, limb-girdle dystrophy, inflammatory myopathy, unexplained high CK, infertility, or metabolic disease, while also raising unresolved questions about reduced penetrance and pleiotropy. (zanovello2023unexpectedfrequencyof pages 1-2)

Major gaps are the absence of an approved disease-modifying therapy; limited prospective, ethnically diverse natural-history cohorts; uncertain penetrance of borderline repeats; lack of validated surrogate endpoints; sparse female-carrier and quality-of-life data; and limited human single-cell, spatial, and longitudinal multi-omic datasets. Registry and preclinical signals should not be conflated with clinical benefit.

References

1. (pradat2020thefrenchnational pages 1-2): P. Pradat, E. Bernard, P. Corcia, P. Couratier, C. Jublanc, G. Querin, C. Morélot Panzini, F. Salachas, C. Vial, K. Wahbi, P. Bede, C. Desnuelle, Nadine Andoni Giorgia Gianni Thierry Cédric Cyril Jean Cl Le Forestier Echaniz-Laguna Querin Sorarù Perez Ra, N. le Forestier, A. Echaniz-Laguna, G. Querin, G. Soraru', T. Perez, Cédric Ramos, C. Goizet, J. Desport, M. Pugeat, B. Pichon, S. Maniez, J. Robillard, C. Coupé, Laurence Laurier Betram, Sandra Roy Bellina, N. Lévêque, J. Penot, and Valérie Goutines Caramel. The french national protocol for kennedy’s disease (sbma): consensus diagnostic and management recommendations. Orphanet Journal of Rare Diseases, Apr 2020. URL: https://doi.org/10.1186/s13023-020-01366-z, doi:10.1186/s13023-020-01366-z. This article has 75 citations and is from a peer-reviewed journal.

2. (zanovello2023unexpectedfrequencyof pages 1-2): Matteo Zanovello, Kristina Ibáñez, Anna-Leigh Brown, Prasanth Sivakumar, Alessandro Bombaci, Liana Santos, Joke J F A van Vugt, Giuseppe Narzisi, Ramita Karra, Sonja W Scholz, Jinhui Ding, J Raphael Gibbs, Adriano Chiò, Clifton Dalgard, Ben Weisburd, John C Ambrose, Prabhu Arumugam, Roel Bevers, Marta Bleda, Freya Boardman-Pretty, Christopher R Boustred, Helen Brittain, Mark J Caulfield, Georgia C Chan, Greg Elgar, Tom Fowler, Adam Giess, Angela Hamblin, Shirley Henderson, Tim J P Hubbard, Rob Jackson, Louise J Jones, Dalia Kasperaviciute, Melis Kayikci, Athanasios Kousathanas, Lea Lahnstein, Sarah E A Leigh, Ivonne U S Leong, Javier F Lopez, Fiona Maleady-Crowe, Meriel McEntagart, Federico Minneci, Loukas Moutsianas, Michael Mueller, Nirupa Murugaesu, Anna C Need, Peter O’Donovan, Chris A Odhams, Christine Patch, Mariana Buongermino Pereira, Daniel Perez-Gil, John Pullinger, Tahrima Rahim, Augusto Rendon, Tim Rogers, Kevin Savage, Kushmita Sawant, Richard H Scott, Afshan Siddiq, Alexander Sieghart, Samuel C Smith, Alona Sosinsky, Alexander Stuckey, Mélanie Tanguy, Ana Lisa Taylor Tavares, Ellen R A Thomas, Simon R Thompson, Arianna Tucci, Matthew J Welland, Eleanor Williams, Katarzyna Witkowska, Suzanne M Wood, Wouter Van Rheenen, Sara L Pulit, Annelot M Dekker, Ahmad Al Khleifat, William J Brands, Alfredo Iacoangeli, Kevin P Kenna, Ersen Kavak, Maarten Kooyman, Russell L McLaughlin, Bas Middelkoop, Matthieu Moisse, Raymond D Schellevis, Aleksey Shatunov, William Sproviero, Gijs H P Tazelaar, Rick A A Van der Spek, Perry T C Van Doormaal, Kristel R Van Eijk, Joke Van Vugt, A Nazli Basak, Ian P Blair, Jonathan D Glass, Orla Hardiman, Winston Hide, John E Landers, Jesus S Mora, Karen E Morrison, Stephen Newhouse, Wim Robberecht, Christopher E Shaw, Pamela J Shaw, Philip Van Damme, Michael A Van Es, Naomi R Wray, Ammar Al-Chalabi, Leonard H Van den Berg, Jan H Veldink, Michael G Hanna, Linda Greensmith, Hemali Phatnani, Jan H Veldink, Bryan J Traynor, James Polke, Henry Houlden, Pietro Fratta, and Arianna Tucci. Unexpected frequency of the pathogenic ar cag repeat expansion in the general population. Brain, 146:2723-2729, Feb 2023. URL: https://doi.org/10.1093/brain/awad050, doi:10.1093/brain/awad050. This article has 37 citations and is from a highest quality peer-reviewed journal.

3. (NCT06169046 chunk 1): Gianni Soraru. A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy. Gianni Soraru. 2024. ClinicalTrials.gov Identifier: NCT06169046

4. (hashizume2020diseasemechanismbiomarker pages 8-12): Atsushi Hashizume, Kenneth H Fischbeck, Maria Pennuto, Pietro Fratta, and Masahisa Katsuno. Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (sbma). Journal of Neurology, Neurosurgery & Psychiatry, 91:1085-1091, Sep 2020. URL: https://doi.org/10.1136/jnnp-2020-322949, doi:10.1136/jnnp-2020-322949. This article has 73 citations.

5. (cantara2024antisenseoligonucleotides(asos) pages 14-16): Silvia Cantara, Giorgia Simoncelli, and Claudia Ricci. Antisense oligonucleotides (asos) in motor neuron diseases: a road to cure in light and shade. International Journal of Molecular Sciences, Apr 2024. URL: https://doi.org/10.3390/ijms25094809, doi:10.3390/ijms25094809. This article has 47 citations.

6. (NCT06862596 chunk 1): Masahisa Katsuno. Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy. Masahisa Katsuno. 2025. ClinicalTrials.gov Identifier: NCT06862596

7. (querin2017kennedydisease(xlinked pages 1-5): G. Querin, Gianni Sorarù, and P. Pradat. Kennedy disease (x-linked recessive bulbospinal neuronopathy): a comprehensive review from pathophysiology to therapy. Revue neurologique, 173 5:326-337, May 2017. URL: https://doi.org/10.1016/j.neurol.2017.03.019, doi:10.1016/j.neurol.2017.03.019. This article has 52 citations and is from a peer-reviewed journal.

8. (hashizume2020diseasemechanismbiomarker pages 1-5): Atsushi Hashizume, Kenneth H Fischbeck, Maria Pennuto, Pietro Fratta, and Masahisa Katsuno. Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (sbma). Journal of Neurology, Neurosurgery & Psychiatry, 91:1085-1091, Sep 2020. URL: https://doi.org/10.1136/jnnp-2020-322949, doi:10.1136/jnnp-2020-322949. This article has 73 citations.

9. (querin2017kennedydisease(xlinked pages 5-9): G. Querin, Gianni Sorarù, and P. Pradat. Kennedy disease (x-linked recessive bulbospinal neuronopathy): a comprehensive review from pathophysiology to therapy. Revue neurologique, 173 5:326-337, May 2017. URL: https://doi.org/10.1016/j.neurol.2017.03.019, doi:10.1016/j.neurol.2017.03.019. This article has 52 citations and is from a peer-reviewed journal.

10. (badders2018selectivemodulationof pages 1-3): Nisha M Badders, Ane Korff, Helen C Miranda, Pradeep K Vuppala, Rebecca B Smith, Brett J Winborn, Emmanuelle R Quemin, Bryce L Sopher, Jennifer Dearman, James Messing, Nam Chul Kim, Jennifer Moore, Brian D Freibaum, Anderson P Kanagaraj, Baochang Fan, Heather Tillman, Ping-Chung Chen, Yingzhe Wang, Burgess B. Freeman III, Yimei Li, Hong Joo Kim, Albert R La Spada, and J Paul Taylor. Selective modulation of the androgen receptor activation function-2 domain rescues degeneration in spinal bulbar muscular atrophy. Nature medicine, 24:427-437, Mar 2018. URL: https://doi.org/10.1038/nm.4500, doi:10.1038/nm.4500. This article has 57 citations and is from a highest quality peer-reviewed journal.

11. (querin2017kennedydisease(xlinked pages 12-15): G. Querin, Gianni Sorarù, and P. Pradat. Kennedy disease (x-linked recessive bulbospinal neuronopathy): a comprehensive review from pathophysiology to therapy. Revue neurologique, 173 5:326-337, May 2017. URL: https://doi.org/10.1016/j.neurol.2017.03.019, doi:10.1016/j.neurol.2017.03.019. This article has 52 citations and is from a peer-reviewed journal.

12. (NCT05517603 chunk 1): A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients. AnnJi Pharmaceutical Co., Ltd.. 2023. ClinicalTrials.gov Identifier: NCT05517603

13. (cortes2014motorneurondegeneration pages 1-2): Constanza J Cortes and Albert R La Spada. Motor neuron degeneration in spinal and bulbar muscular atrophy is a skeletal muscle-driven process: relevance to therapy development and implications for related motor neuron diseases. Rare Diseases, 2:e962402, Jan 2014. URL: https://doi.org/10.4161/2167549x.2014.962402, doi:10.4161/2167549x.2014.962402. This article has 9 citations.

14. (iida2019srcinhibitionattenuates pages 1-2): M. Iida, K. Sahashi, Naohide Kondo, H. Nakatsuji, G. Tohnai, Y. Tsutsumi, S. Noda, Ayuka Murakami, Kazunari Onodera, Y. Okada, M. Nakatochi, Yuka Tsukagoshi Okabe, S. Shimizu, M. Mizuno, H. Adachi, H. Okano, G. Sobue, and M. Katsuno. Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy. Nature Communications, Sep 2019. URL: https://doi.org/10.1038/s41467-019-12282-7, doi:10.1038/s41467-019-12282-7. This article has 24 citations and is from a highest quality peer-reviewed journal.

15. (hashizume2020diseasemechanismbiomarker pages 15-19): Atsushi Hashizume, Kenneth H Fischbeck, Maria Pennuto, Pietro Fratta, and Masahisa Katsuno. Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (sbma). Journal of Neurology, Neurosurgery & Psychiatry, 91:1085-1091, Sep 2020. URL: https://doi.org/10.1136/jnnp-2020-322949, doi:10.1136/jnnp-2020-322949. This article has 73 citations.

16. (NCT00303446 chunk 1): Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA). National Institute of Neurological Disorders and Stroke (NINDS). 2006. ClinicalTrials.gov Identifier: NCT00303446

17. (NCT06411912 chunk 1): A Study of NIDO-361 in Patients With SBMA. Nido Biosciences, Inc.. 2024. ClinicalTrials.gov Identifier: NCT06411912

18. (NCT02024932 chunk 1): Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy. Novartis Pharmaceuticals. 2014. ClinicalTrials.gov Identifier: NCT02024932

19. (querin2017kennedydisease(xlinked pages 19-22): G. Querin, Gianni Sorarù, and P. Pradat. Kennedy disease (x-linked recessive bulbospinal neuronopathy): a comprehensive review from pathophysiology to therapy. Revue neurologique, 173 5:326-337, May 2017. URL: https://doi.org/10.1016/j.neurol.2017.03.019, doi:10.1016/j.neurol.2017.03.019. This article has 52 citations and is from a peer-reviewed journal.

20. (querin2017kennedydisease(xlinked pages 15-19): G. Querin, Gianni Sorarù, and P. Pradat. Kennedy disease (x-linked recessive bulbospinal neuronopathy): a comprehensive review from pathophysiology to therapy. Revue neurologique, 173 5:326-337, May 2017. URL: https://doi.org/10.1016/j.neurol.2017.03.019, doi:10.1016/j.neurol.2017.03.019. This article has 52 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.